Pulmicort 0,25 mg/ml & 0,5 mg/ml Suspension
PDF Leaflet Revision Date: 02 February 2015
Clinical Summary
Quick overview from the medicine insert
Indication
Management of asthma in patients inadequately controlled by bronchodilators.
Dosage (summary)
Adults: 0.5-1 mg twice daily; Children: 0.25-0.5 mg twice daily.
Special Populations
- Children under 12 months
- Severely compromised liver function
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established; excreted in breast milk.
Key Drug Interactions
- CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) increase exposure
Contraindications
- Lung tuberculosis
- Fungal and viral infections in airways
- Hypersensitivity to budesonide
Common side effects
- Mild throat irritation
- Hoarseness
- Coughing
- Candida infection
Counselling Points
- Rinse mouth after use to prevent thrush
- Wash face after using nebuliser mask
Serious warnings
- Not for rapid relief of acute asthma episodes
- Risk of adrenal insufficiency during withdrawal
Important Disclaimer
The Pulmicort 0,25 mg/ml & 0,5 mg/ml Suspension professional information leaflet below is the property of Astrazeneca Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
